Ignite Creation Date:
2024-05-05 @ 6:35 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00501735
Status:
COMPLETED
Last Update Posted:
2012-01-23
First Post:
2007-07-12
Brief Title:
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma
Sponsor:
BioCryst Pharmaceuticals
Organization:
BioCryst Pharmaceuticals
Study Overview
Official Title:
Single Agent Phase II Study of Forodesine BCX1777 in the Treatment of Cutaneous T-Cell Lymphoma
Status:
COMPLETED
Status Verified Date:
2012-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase II non-randomized open-label single-arm trial that will be conducted at up to 50 sites in North America Europe and Australia This study is designed to assess objective response OR complete response CR or partial response PR in subjects with cutaneous manifestations of CTCL with a requirement for maintenance of such objective response for at least 28 days in subjects with stage IIB III and IVA CTCL Additionally this study will evaluate the safety and tolerability of CTCL subjects Stages IB IIA IIB III or IVA treated with oral forodesine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None